Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Capital Leases (2016 - 2018)

ImmunityBio (IBRX) has disclosed Capital Leases for 3 consecutive years, with $5.9 million as the latest value for Q4 2018.

  • On a quarterly basis, Capital Leases rose 241.47% to $5.9 million in Q4 2018 year-over-year; TTM through Dec 2018 was $5.9 million, a 241.47% increase, with the full-year FY2018 number at $5.9 million, up 241.47% from a year prior.
  • Capital Leases was $5.9 million for Q4 2018 at ImmunityBio, down from $6.1 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $6.3 million in Q2 2018 to a low of $1.7 million in Q1 2018.
  • A 3-year average of $3.2 million and a median of $2.0 million in 2016 define the central range for Capital Leases.
  • Peak YoY movement for Capital Leases: fell 24.1% in 2017, then surged 241.47% in 2018.
  • ImmunityBio's Capital Leases stood at $2.0 million in 2016, then dropped by 14.02% to $1.7 million in 2017, then soared by 241.47% to $5.9 million in 2018.
  • Per Business Quant, the three most recent readings for IBRX's Capital Leases are $5.9 million (Q4 2018), $6.1 million (Q3 2018), and $6.3 million (Q2 2018).